Aim: To investigate the association between plasma AAT level and glaucoma. Methods: 163 glaucoma patients and 111 healthy controls were recruited. The plasma AAT levels were measured by ELISA. Results: Plasma AAT level was significantly higher in glaucoma patients than those in healthy controls (p < 0.001). Patients with higher plasma AAT level exhibited severer disease stage (early vs. severe: p < 0.05; H-P-A; early vs. severe: p < 0.05; early vs. end-stage: p < 0.01; AGIS). ROC curves yielded that AAT can distinguish patients with early glaucoma from those with advanced glaucoma (early vs. severe: AUC: 0.616; H-P-A; early vs. severe: AUC: 0.763; early vs. end-stage: AUC: 0.660; AGIS). Conclusion: Plasma AAT is a useful biomarker for the identification of glaucoma severity.
基金：
National Natural Science Foundation of China [U19A2004, 81970803, 82370560]; Open Project of Sichuan Provincial Key Laboratory for Clinical Immunology Translational Medicine [LCMYZHYX-KFKT202204]; Foundation of Sichuan Science and Technology Department [2022NSFSC1380]
第一作者机构：[1]Sichuan Univ, West China Sch Basic Med Sci & Forens Med, Dept Immunol, Chengdu 610041, Peoples R China
通讯作者：
通讯机构：[2]Univ Elect Sci & Technol China, Sichuan Prov Peoples Hosp, Clin Immunol Translat Med Key Lab Sichuan Prov, Chengdu 611731, Peoples R China[3]Univ Elect Sci & Technol China, Med Engn Cooperat Appl Med Res Ctr, Chengdu 610054, Peoples R China
推荐引用方式(GB/T 7714)：
Yuan Hang,Li An,Chen Lingling,et al.α-1 antitrypsin is promising for the identification of glaucoma severity and is associated with glaucomatous neural damage[J].BIOMARKERS IN MEDICINE.2024,18(10-12):545-553.doi:10.1080/17520363.2024.2347190.
APA：
Yuan, Hang,Li, An,Chen, Lingling,Wang, Zuo,Zhu, Xiong...&He, Chong.(2024).α-1 antitrypsin is promising for the identification of glaucoma severity and is associated with glaucomatous neural damage.BIOMARKERS IN MEDICINE,18,(10-12)
MLA：
Yuan, Hang,et al."α-1 antitrypsin is promising for the identification of glaucoma severity and is associated with glaucomatous neural damage".BIOMARKERS IN MEDICINE 18..10-12(2024):545-553
